Bispecific antibodies
Unlock the power of dual targeting with our BsAb solutions that can help design, engineer, and optimize your antibody therapeutic to target two distinct sites / markers simultaneously for enhanced efficacy and specificity.
Helping you overcome the challenges seen in dual binding, antibody screening, tissue tropism, pharmacodynamics, analysis, and overall complexity within the process.
Products and Platforms
CHOSOURCE Platform
The CHOSOURCE™ expression platform enables rapid generation of clones expressing high levels of recombinant therapeutic protein during stable cell line development.
Learn more
Cell Counting & Image Cytometry Instruments
Revvity offers a leading portfolio of automated cell counters, image cytometry systems, and cell counting reagents and consumables. Together, they provide fast, accurate and efficient ways to assess cell health and viability.
Learn more
マイクロプレートリーダー
Revvityのプレートリーダー製品群は、今日のラボの多様なアッセイ要件に対応する最新の検出技術を備えています。
Learn more
ハイコンテントスクリーニング装置
ハイコンテント解析（HCA）またはハイコンテントスクリーニング（HCS）は、ハイスループットの自動イメージングと解析を組み合わせ、シングルセルレベルで定量的なマルチパラメトリックデータを抽出します。
Learn more
マイクロ流体によるタンパク質特性評価
タンパク質は、そのサイズ、分子構造、物理化学的性質が互いに異なります。これらの違いにより、分離と同定によるタンパク質の分析と特性解析が可能になります。
Learn more
Cellular Imaging Software
Revvityは、より効果的かつ効率的に画像データを取得、可視化、解析、共有するための洗練された細胞イメージングおよび画像解析ソフトウェアを提供しています。
Learn more
In vivo イメージング
生物学的プロセスと疾患の進行を追跡、モニタリング、可視化することは、生物学の理解を深めるだけでなく、開発プロセスの早い段階で潜在的な新薬候補の有効性を評価する上で極めて重要です。
Learn more
イムノアッセイ
1950年代にイムノアッセイが導入されて以来、イムノアッセイは研究や創薬に不可欠な要素となってきました。
Learn more
Content
Addressing the challenges in modern biotherapeutic development
Charter a course to biotherapeutic antibody development success
The rise of bispecific antibodies for use as groundbreaking therapies continues to grow with more than 100 bispecific antibodies currently in development. This is thanks to their remarkable versatility from having dual binding sites targeting two different epitopes, providing advantages such as reducing resistance issues, increased specificity, and identifying unique combinations of drug targets.
However, navigating the intricate challenges of bispecific antibodies is no small feat. That’s why we’ve created this infographic that will aid you on the journey, equipping you with the knowledge to overcome the obstacles along the way and achieve excellence in bispecific antibody development.
Learn more about:
<ul>
<li>Stages that make up the bispecific antibody path</li>
<li>Challenges and considerations faced in development</li>
<li>Various solutions and technologies available</li>
</ul>
<em>For research use only. Not for use in diagnostic procedures.</em>
Learn more
Addressing the challenges of bispecific antibody characterization with high-throughput platforms
Bispecific antibodies (bsAbs) have emerged as an attractive class of therapeutic agents with the potential to revolutionize the treatment of various disorders. While the concept of bsAbs has been around for several decades, it has taken time for the technology and understanding of antibody engineering to advance to a point where its practical application has become feasible.
The development of bsAbs demands intricate screening processes to identify candidates with desired binding properties, ensuring they induce specific biological activities. Additionally, achieving optimal tissue tropism and potency requires careful consideration of factors such as antibody size, affinity, and the implementation of innovative characterization strategies.
In this context, this whitepaper explores novel approaches contributing to bsAb characterization, offering real-world examples that highlight their practical applications.
<em>For research use only. Not for use in diagnostic procedures.</em>
Learn more
Higher throughput bioanalytical methods accelerate the development and evaluation of advanced biotherapeutics
Successful development of advanced biotherapeutics relies on extensive characterization and tight quality control. Characterizing binding properties of complex biomolecules is a critical step. Biophysical data combined with functional assays are needed to predict efficacy and potency, optimize drug delivery, assess critical quality attributes, and improve biologics drug design.Traditional approaches have limited use in a complex biological environment with multiple interactions. Our speakers have developed and implemented more sensitive and higher throughput technologies:<strong>In this webinar our speakers show:</strong>
<ul>
<li>A method of testing the interaction of a lead biosimilar antibody candidate versus a commercially available antibody</li>
<li>The development of a more sensitive assay to determine the level of binding activity and for QC lot release</li>
<li>An expression platform to aid early-stage clone screening and protein characterization</li>
<li>A higher-throughput platform to streamline cell line development and characterization workflows </li>
</ul>
<strong>Speakers: </strong>
<ul>
<li>Ron Morena, Manager in Analytical Bioassay – Tanvex CDMO</li>
<li>Dr. Neha Mishra, Senior Scientist, BioProduction - Revvity</li>
</ul>
<em>For research use only. Not for use in diagnostic procedures.</em>
Learn more
Streamlining the development of bispecific antibodies from expression to quality assessment with Revvity’s biotherapeutic workflow solutions
In this application note we show how the CHOSOURCE™ TnT Transposon Technology was used to express an asymmetric 4-chain bispecific antibody in the CHOSOURCE GS KO host cell line.
Additionally, Revvity’s LabChip GXII Touch HT system is used to rapidly characterize the expressed proteins, showing that in combination with CHOSOURCE, biotherapeutic workflows can be streamlined and accelerated.
<em>For research use only. Not for use in diagnostic procedures.</em>
Learn more
Antibody drug conjugates
Revolutionize your therapeutic development with our ADC solutions that can help you discover, develop, and evaluate payload, efficacy and toxicology/safety studies.
Our solutions, including CRISPR tools and screening services, generation of cell models, high-content screening, linker-drug characterization, antibody conjugation, data modelling, potency and detection platforms, and antibody binding and functional assays, can support the precision and reliability required at each stage of your workflow, from discovery through preclinical development.
Products and Platforms
Antibody Drug Conjugate Services
In the discovery of oncology therapeutics, Antibody-drug conjugates (ADCs) are rapidly gaining momentum, with hundreds of candidates advancing through clinical development.
Learn more
CHOSOURCE Platform
The CHOSOURCE™ expression platform enables rapid generation of clones expressing high levels of recombinant therapeutic protein during stable cell line development.
Learn more
Cell Counting & Image Cytometry Instruments
Revvity offers a leading portfolio of automated cell counters, image cytometry systems, and cell counting reagents and consumables. Together, they provide fast, accurate and efficient ways to assess cell health and viability.
Learn more
イムノアッセイ
1950年代にイムノアッセイが導入されて以来、イムノアッセイは研究や創薬に不可欠な要素となってきました。
Learn more
ハイコンテントスクリーニング装置
ハイコンテント解析（HCA）またはハイコンテントスクリーニング（HCS）は、ハイスループットの自動イメージングと解析を組み合わせ、シングルセルレベルで定量的なマルチパラメトリックデータを抽出します。
Learn more
マイクロ流体によるタンパク質特性評価
タンパク質は、そのサイズ、分子構造、物理化学的性質が互いに異なります。これらの違いにより、分離と同定によるタンパク質の分析と特性解析が可能になります。
Learn more
Signals
Simplify data capture, processing, and analysis at each ADC development stage, and identify the most promising antibodies, linkers, and payloads.
Learn more
Content
Antibody drug conjugates: A novel targeted approach to cancer therapy
The steady rise in antibody-drug conjugate (ADC) candidates over the past couple of decades reflects the increasing recognition of their potential in
Learn more
Preclinical screening platforms for antibody-drug conjugate therapeutics
Antibody-Drug Conjugates (ADCs) are at the cutting edge of oncology research, offering a groundbreaking approach to targeting cancer cells while minimizing damage to healthy tissue.
This white paper explores the latest advancements in ADC development, including innovations in drug delivery, strategies for overcoming treatment resistance, and preclinical screening platforms to optimize efficacy.
If you're looking for insights into the next breakthrough in cancer medicine, this is essential reading.
<em>For research use only. Not for use in diagnostic procedures.</em>
Learn more
RNA vaccines and therapeutics
Enhance your RNA therapeutics and vaccine workflows with solutions that can help you produce a safer and efficient approach. With the right support and expertise benefit from the versatility and ease of adaptability a mRNA or other RNA modality platforms can provide.
We can help in target identification, characterization, assay development for early-stage research and screening, as well as preclinical development workflows including evaluation of immunogenicity to support your modality’s efficacy and safety. Our tools and services can address your RNA payload evaluation, optimization and delivery.
Products and Platforms
マイクロ流体核酸分析
従来のゲル分離を簡略化し、わずかな時間でデータの再現性を向上させることができます。LabChip™自動マイクロ流体キャピラリー電気泳動技術を利用した分離では、ゲノムサンプルを数十秒で分析できます。
Learn more
Lentivirus
Lentiviruses are a subtype of retroviruses which have a single stranded RNA genome that encode for three major structural genes: gag, pol, and env.
Learn more
AAV
Our high-quality premade AAV particles are ideal for pilot studies, or as standardized test material for product, process, or assay development.
Learn more
RNA Interference
Dharmacon™ siRNA, shRNA, and microRNA-based reagents, leading the field for nearly 30 years providing highly specific and efficient gene silencing.
Learn more
Oligonucleotide Custom Synthesis
Leveraging almost 30 years of experience as a leading provider in oligo design and synthesis, Revvity's oligo synthesis team offers a range of services.
Learn more
イムノアッセイ
1950年代にイムノアッセイが導入されて以来、イムノアッセイは研究や創薬に不可欠な要素となってきました。
Learn more
マイクロプレートリーダー
Revvityのプレートリーダー製品群は、今日のラボの多様なアッセイ要件に対応する最新の検出技術を備えています。
Learn more
Content
An emerging therapeutic modality - RNA carves its path out of the paradigm
RNA-based therapeutics have garnered significant attention in recent years, fueled by the success of the mRNA COVID-19 vaccines. The development of therapeutics for a broad range of other conditions, including monogenic diseases, metabolic disorders, and cancer, are now being made possible due to advances in RNA-mediated genome editing tools and technologies.
Considering the growing interest in RNA therapies, our latest article highlights several promising classes of RNA therapeutic, including RNAi, CRISPR, base editing, and mRNA vaccines, as well as the potential to combine RNA technologies with CAR-T.
<em>For research use only. Not for use in diagnostic procedures.</em>
Learn more
Rethinking the vaccine landscape
Infectious diseases, which are those caused by pathogenic microorganisms such as viruses, bacteria, parasites, or fungi, have threatened humanity throughout history and are one of the leading causes of death worldwide.1 This is especially the case in low-income countries, often due to the consequences of poverty such as poor nutrition, sanitation, and lack of health education. With the exception of clean, safe water, vaccines are considered one of the best prophylaxes to combat infectious diseases, minimize or prevent transmission, and reduce mortality rates.
<em>For research use only. Not for use in diagnostic procedures.</em>
Learn more
Novel RNA therapeutic modalities
Explore the various modalities and advances in therapy that have been enabled by RNA.
Learn more
